Phase II trial of vinflunine in relapsed small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 874-878

  Spigel, David R ^a,b   Hainsworth, John D ^a,b   Lane, Cassie M ^a   Clark, Bobby ^a   Burris, Howard A ^a,b   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

Author keywords

Relapse; Single agent therapy; Small cell lung cancer; Vinflunine

Indexed keywords

VINFLUNINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPONATREMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, SMALL CELL; DISEASE FREE SURVIVAL; DRUG EFFECTS; LUNG NEOPLASMS; MICROTUBULE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICROTUBULES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VINBLASTINE;

EID: 77953144808     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d86b76     Document Type: Article

References (20)

1. Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
2. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
3. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-2092.
4. O'Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447.
5. Etievant C, Barret JM, Kruczynski A, et al. Vinflunine (20', 20'-difluoro-3', 4'-dihydrovinorelbine), a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs 1998;16:3-17.
6. Jacquesy JC, Fahy I. Cancer: superacidic generation of new antitumour agents. In PF Torrens, (Ed.), Biomedical Chemistry: Applying Chemical Principals to the Understanding and Treatment of Disease. New York, NY: Wiley Interscience, 2000. Pp. 227-245.
7. Aggarwal A, Kruczynski A, Frankfurter A, et al. Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine. Invest New Drugs 2008;26:319-330.
8. Jordan MA, Horwitz SB, Lobert S, et al. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol 2008;35: S6-S12.
9. Lobert S, Ingram JW, Hill BT, et al. A comparison of thermodynamic parameters for vinorelbine-and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998;53:908-915.
10. Lobert S, Puozzo C. Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol 2008;35: S28-S33.
11. Bellmunt Molins J, von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol (Meeting Abstracts) 2008;26:5028.
12. Kaleta R, Chung HC, Park SR, et al. Single agent IV vinflunine (VFL) in the second-line treatment of patients (pts) with advanced gastric cancer (AGC) : initial results of a phase II trial. J Clin Oncol (Meeting Abstracts) 2008;26:15533.
13. Krzakowski M, Douillard J, Ramlau R, et al. Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol (Meeting Abstracts) 2007;25:7511.
14. Meluch AA, Spigel DR, Burris HA III, et al. Vinflunine (VFL) as salvage chemotherapy in hormone-refractory prostate cancer (HRPC). J Clin Oncol (Meeting Abstracts) 2008;26:16059.
15. Saliba F, Paule B, Adam R, et al. Vinflunine in patients with advanced unresectable hepatocellular carcinoma and liver impairment. J Clin Oncol (Meeting Abstracts) 2007;25:15023.
16. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007;25:4751-4756.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
18. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
20. Joppert M, Knapp M, Dakhil SR, et al. A phase II trial of single-agent vinflunine as second-line treatment for advanced non-small cell lung cancer (An International Oncology Network Study, #I-05-009). J Clin Oncol (Meeting Abstracts) 2008;26:19033.